Main Menu

Professor Johann de Bono key publications


Robinson, D., Van Allen, EM., Wu, YM., Schultz, N., Lonigro, RJ., Mosquera, JM., Montgomery, B., Taplin, ME., Pritchard, CC., Attard, G., et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell, Vol.161, pp.1215–1228, Show Abstract

Fizazi, K., Scher, HI., Miller, K., Basch, E., Sternberg, CN., Cella, D., Forer, D., Hirmand, M. & de Bono, JS. (2014) Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol, Vol.15, pp.1147–1156, Show Abstract

Omlin, A., Pezaro, C., Mukherji, D., Mulick Cassidy, A., Sandhu, S., Bianchini, D., Olmos, D., Ferraldeschi, R., Maier, G., et al. (2013) Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol, Vol.64, pp.300–306, Show Abstract

Ryan, CJ., Smith, MR., de Bono, JS., Molina, A., Logothetis, CJ., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, JM., Ng, S., et al. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, Vol.368, pp.138-148, Show Abstract

Logothetis, CJ., Basch, E., Molina, A., Fizazi, K., North, SA., Chi, KN., Jones, RJ., Goodman, OB., Mainwaring, PN., Sternberg, CN., et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol, Vol.13, pp.1210–1217, Show Abstract

Olmos, D., Brewer, D., Clark, J., Danila, DC., Parker, C., Attard, G., Fleisher, M., Reid, AH., Castro, E., Sandhu, SK., et al. (2012) Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol, Vol.13, pp.1114–1124, Show Abstract

Scher, HI., Fizazi, K., Saad, F., Taplin, ME., Sternberg, CN., Miller, K., de Wit, R., Mulders, P., Chi, KN., Shore, ND., et al. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, Vol.367, pp.1187–1197, Show Abstract

de Bono, JS., Logothetis, CJ., Molina, A., Fizazi, K., North, S., Chu, L., Chi, KN., Jones, RJ., Goodman, OB Jr., Saad, F., et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, Vol.364, pp.1995–2005, Show Abstract

de Bono, JS. & Ashworth, A. (2010) Translating cancer research into targeted therapeutics. Nature, Vol.467, pp.543–549, Show Abstract

de Bono, JS., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, JP., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, MJ., Shen, L., et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, Vol.376, pp.1147–1154, Show Abstract

Reid, AH., Attard, G., Danila, DC., Oommen, NB., Olmos, D., Fong, PC., Molife, LR., Hunt, J., Messiou, C., Parker, C., et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol, Vol.28, pp.1489–1495, Show Abstract

Fong, PC., Boss, DS., Yap, TA., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, MJ., et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med, Vol.361, pp.123–134, Show Abstract